Photo: Pixabay (Representative Image)
KATHMANDU: One in five people with depression have suicidal thoughts despite treatment with antidepressants. This is shown by a new study from iPSYCH. The results can be used to examine whether more targeted treatment could be provided for patients where medication does not have a sufficient effect.
Antidepressants are used in particular against moderate to severe depressions. A new study from the Danish national research project iPSYCH shows that twenty percent of people with depression have suicidal thoughts, even though they are treated with antidepressants.
The researchers studied 811 patients who had moderate to severe depression and were treated with two different antidepressants over a twelve-week period. Weekly measurements were taken of the level of suicidal thoughts.
“We were able to place the patients in five categories based on how their suicidal thoughts developed during the treatment,” says Trine Madsen.
Slightly more than half of the patients experienced no or low levels of suicidal thoughts during the twelve weeks of treatment, while one in four had suicidal thoughts at the beginning of the study but responded well to the medicine already after a few weeks.
The remaining twenty percent of patients could be further categorized, with ten percent experiencing an increased level of suicidal thoughts throughout the whole study, and ten percent who experienced shifts between higher and lower levels of suicidal thoughts.
The results have just been published in the scientific journal the Journal of Clinical Psychiatry.
The researchers indicate that future studies should investigate whether patients may experience suicidal thoughts for even longer than the twelve-week period over which the current study extended.
“Some studies have suggested that people with mental disorders can have suicidal thoughts for a number of years. In addition, there should be studies of whether more intensive treatment involving increased pharmacological and/or psychological treatment may lead to a better response in patients who don’t respond to the medicine within the first few weeks,” says Ole Köhler-Forsberg.